Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL

Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin’s lymphoma (NHL). 30 ~ 40% of DLBCL patients were resistant to the standard R-CHOP regimen or recurrence after remission. It is currently believed that drug resistance is the main cause of the recurrence and refractory o...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jing, Gu, Yan, Chen, Baoan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9976586/
https://www.ncbi.nlm.nih.gov/pubmed/36873252
http://dx.doi.org/10.2147/CMAR.S400013
_version_ 1784899118481539072
author Zhang, Jing
Gu, Yan
Chen, Baoan
author_facet Zhang, Jing
Gu, Yan
Chen, Baoan
author_sort Zhang, Jing
collection PubMed
description Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin’s lymphoma (NHL). 30 ~ 40% of DLBCL patients were resistant to the standard R-CHOP regimen or recurrence after remission. It is currently believed that drug resistance is the main cause of the recurrence and refractory of DLBCL (R/R DLBCL). With the increased understanding of DLBCL biology, tumor microenvironment and epigenetics, some new therapies and drugs like molecular and signal pathway target therapy, chimeric antigen receptor (CAR) T-cell therapy, immune checkpoint inhibitors, antibody drug-conjugate and tafasitamab have been used for R/R DLBCL. This article will review the drug resistance mechanism and novel targeted drugs and therapies of DLBCL.
format Online
Article
Text
id pubmed-9976586
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-99765862023-03-02 Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL Zhang, Jing Gu, Yan Chen, Baoan Cancer Manag Res Review Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin’s lymphoma (NHL). 30 ~ 40% of DLBCL patients were resistant to the standard R-CHOP regimen or recurrence after remission. It is currently believed that drug resistance is the main cause of the recurrence and refractory of DLBCL (R/R DLBCL). With the increased understanding of DLBCL biology, tumor microenvironment and epigenetics, some new therapies and drugs like molecular and signal pathway target therapy, chimeric antigen receptor (CAR) T-cell therapy, immune checkpoint inhibitors, antibody drug-conjugate and tafasitamab have been used for R/R DLBCL. This article will review the drug resistance mechanism and novel targeted drugs and therapies of DLBCL. Dove 2023-02-25 /pmc/articles/PMC9976586/ /pubmed/36873252 http://dx.doi.org/10.2147/CMAR.S400013 Text en © 2023 Zhang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Zhang, Jing
Gu, Yan
Chen, Baoan
Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL
title Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL
title_full Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL
title_fullStr Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL
title_full_unstemmed Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL
title_short Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL
title_sort drug-resistance mechanism and new targeted drugs and treatments of relapse and refractory dlbcl
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9976586/
https://www.ncbi.nlm.nih.gov/pubmed/36873252
http://dx.doi.org/10.2147/CMAR.S400013
work_keys_str_mv AT zhangjing drugresistancemechanismandnewtargeteddrugsandtreatmentsofrelapseandrefractorydlbcl
AT guyan drugresistancemechanismandnewtargeteddrugsandtreatmentsofrelapseandrefractorydlbcl
AT chenbaoan drugresistancemechanismandnewtargeteddrugsandtreatmentsofrelapseandrefractorydlbcl

Ejemplares similares